Tunitas Therapeutics Inc.
Inhibiting allergic reactions at the cellular level
This article was originally published in Start Up
Tunitas Therapeutics Inc. thinks its research could go a long way toward relieving the suffering of the 40% of Americans with allergies to one or more common inhalant or food allergan. The San Francisco-based biopharma is developing precisely targeted fusion proteins that are designed to alter the natural course of allergic diseases at the cellular level, inhibiting allergic reactions from occurring.